Omnes Capital's investments

Sector 
Pharma
Entry Date 
2019
Business 
Venture Capital

NH TherAguix

Nanomedicine for cancer radiotherapy
Founded in December 2015, and backed by Pulsalys, the technology transfer acceleration company from Lyon Saint-Etienne, NH TherAguix originates a nanomedicine innovation, the AGuIX drug candidate. This product, thanks to its nanometric structure, allows an IV administration and combines three essential attributes to fight tumours: targeting, imaging and treatment. The AGuIX technology is therefore part of the theranostics concept, which relates to a combination of therapy (radiosensitizing effect) and diagnostics (MRI imaging), and more widely in the personalized medicine of tomorrow.
Latest news
Sector 
Pharma
Entry Date 
2019
Business 
Venture Capital

AgomAb Therapeutics

A biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues

AgomAb was founded through a collaboration between argenx and the University of Torino, Italy, based on the groundbreaking work of Paolo Michieli and his translational medicine team. The Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. Based in Ghent Belgium, it is backed by an International syndicate of experienced life sciences venture capital investors.

Latest news
Sector 
Medical devices
Entry Date 
2019
Business 
Venture Capital

Therapixel

Artificial intelligence applied to radiology
Created in 2013 by two former INRIA researchers, Therapixel is a world leader in artificial intelligence applied to radiology. Winner of the DREAM Digital Mammography Challenge in 2017, Therapixel is developing an AI-based service for assisting radiologists review screening mammography for breast cancer.
Latest news
Sector 
Web
Entry Date 
2019
Business 
Venture Capital

Teach on Mars

Europe’s leading mobile-native learning technology provider

Teach on Mars is a 100% mobile-native learning technology provider. Our solution helps today’s organisations connect people with the learning and the communities they need to do their jobs and live their lives better. Winner of numerous industry awards, Teach on Mars is recognised as European leader in the mobile learning space. Since its foundation in 2013, the company has delivered its solution to over 130 blue-chip clients, in 20+ languages across more than 90 countries throughout the globe, and today it has bases in Sophia-Antipolis, Paris, Milan, London, Brussels and Casablanca. 80 Teach on Mars staff and an extensive worldwide network of 50 content and technology partners collaborate to equip organisations with the toolset, mindset and skillset required to create their next-generation learning ecosystem. And because Teach on Mars takes its responsibility for the future of our planet seriously, it invests 1% of its revenues in education projects contributing directly to the United Nations Sustainsable Development Goals.

Latest news
Sector 
Web
Entry Date 
2018
Business 
Venture Capital

GEEV

The first app for donating items between individuals

Thanks to a simple and fun service, "Geevers" can easily give and receive items for free in the proximity of their own homes. Available in Paris, Lyon, Marseille, Lille, Bordeaux, Nantes and Toulouse, GEEV has become an obvious alternative to selling, unnecessary storage and the proliferation of waste in the public space.

Latest news
Sector 
Pharma
Entry Date 
2018
Business 
Venture Capital

Antabio

Biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. This second program has recently received up to $8.9 million funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). 

Latest news
Sector 
Construction and building materials
Entry Date 
2018
Business 
Venture Capital

Nanomakers

Founded in 2010 and based in Rambouillet, the French start-up Nanomakers has been designing and producing since 2012 patented silicon-based nanopowders which transform the mechanical, chemical or thermal properties of materials. Its disruptive technology has made it possible to triple the energy density of Li-ion batteries anodes, or to lighten and reinforce the mechanical properties of certain materials (metal alloys, elastomers) used in various industrial sectors.
Latest news
Sector 
Hardware
Entry Date 
2018
Business 
Venture Capital

Tilkee

Tilkee was founded by Sylvain Tillon and Timothée Saumet in decembre 2013. The company offers a complete suite of document tracking solutions: Tilkee for Sales, Tilkee for Marketing, Tilkee for Jobs and Tilkee for Events. Tilkee currently employs 24 people and is growing in Europe (Germany, United Kingdom, Spain). Tilkee’s clients include EDF, Orange, Schneider Electric, Credit Agricole and Adecco

Latest news
Sector 
SaaS / Cloud
Entry Date 
2018
Business 
Venture Capital

Vsora

Innovative DSP IP solutions

Founded in 2015, VSORA will introduce innovative DSP IP solutions to accelerate the design of complex integrated circuits, prevalent in the mobile, networking and consumer product markets. It has offices in Velizy-Villacoublay.

 

Latest news
Sector 
Pharma
Entry Date 
2012
Business 
Venture Capital

Enterome

Pioneer in personalised medicine harnessing the power of gut microbiome

Based in Paris, Enterome is an innovative theranostics company dedicated to discovering and developing biomarkers to diagnose and treat inflammatory conditions (Crohn’s disease, ulcerative colitis) linked to anomalies in intestinal composition using a unique platform that harnesses the power of the human microbiome. In addition to its inflammatory franchise, the Enterome platform can also be used for a vast range of applications such as monitoring and treating metabolic conditions (fatty liver, obesity, diabetes). 

Latest news

Pages

NewsRoom
Press release
16 December 2020
New primary LBO deal for Omnes and its small cap funds with regional operator Tennaxia, a publisher of SaaS solutions to help listed companies and SMEs / mid-market companies in France with their CSR strategies
New primary LBO deal for Omnes and its small cap funds with regional operator Tennaxia, a publisher of SaaS solutions to help listed companies and SMEs / mid-market companies in France with their CSR strategies
Le Cercle Omnes des Entrepreneurs - January 31, 2018
Publication
Scope, the Omnes Review, July 2020
Press release
24 November 2020
AlgoTherapeutix raises €12M to take ATX01 into clinical development in chemotherapy-induced peripheral neuropathy
AlgoTherapeutix raises €12M to take ATX01 into clinical development in chemotherapy-induced peripheral neuropathy
3 minutes for innovation - FCPI innovation funds : Omnes' new investments
Press release
09 November 2020
Omnes makes its first investment in the Irish renewables market, teaming up with solar PV developer Power Capital Renewable Energy
Omnes makes its first investment in the Irish renewables market, teaming up with solar PV developer Power Capital Renewable Energy
Press release
21 October 2020
Omnes reinvests in Biosyl to finance the creation of a new production site in Auvergne
Omnes reinvests in Biosyl to finance the creation of a new production site in Auvergne

Pages